Organ preservation and local excision for rectal cancer: Long-term oncologic outcomes.

3655 Background: Organ preservation is a desired outcome for rectal cancer patients after neoadjuvant chemoradiotherapy. In patients where a complete response is in question, endoscopically assisted full-thickness local excision offers a great option. Long-term data with this approach is limited. We report our experience with transanal endoscopic microsurgery (TEM) status post chemotherapy. Methods: Between January 2005 and October 2019, from a prospectively maintained rectal cancer database, we identified all patients who underwent TEM for adenocarcinoma after neoadjuvant CRT. Demographic data as well as follow-up interval and oncologic outcomes were reviewed and analyzed. Results: Ninety-two patients who underwent TEM for rectal cancer were included. The mean age was 67 years (32–94), 66% were male, and the mean BMI was 29.3 kg/m² (19.1–43). ASA classifications were II in 38%, III in 51%, and IV in 5% of patients. The mean tumor size was 3.1 cm (1–6) and mean estimated blood loss (EBL) was 29 mL (0–500). Postoperative 30-day morbidity occurred in 6.5% of patients, with no mortalities. The mean follow-up was 57.5 months (0.4-194.5), during which 7.6% of patients developed local recurrence and 6.5% developed systemic metastases. Based on final pathology, 48 patients with a complete pathologic response (ypT0) had local recurrence and distant metastasis rates of 4% and 2%, respectively. In patients with stage I disease (n=35), local recurrence occurred in 11% and distant metastasis occurred in 9%. Stage II patients (n=7) experienced a 14% rate of local recurrence with no distant metastases. Among stage III patients (n=2), both local and distant failure occurred in 50% of cases. Conclusions: TEM after neoadjuvant CRT was associated with excellent oncologic outcomes in patients achieving complete pathologic response. Selected patients with favorable residual disease experienced acceptable recurrence rates, supporting TEM as a potential organ-preserving strategy in this subgroup. In contrast, higher pathologic stage was associated with substantially increased local and distant failure, highlighting the need for strict selection, pathology-driven decision-making, and close surveillance.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-05-27
DOI
https://doi.org/10.1200/jco.2026.44.16_suppl.3655
Primary Topic
Colorectal Cancer Surgical Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Organ preservation and local excision for rectal cancer: Long-term oncologic outcomes.

Erik L. Zeger, Avihai Moscovici, Tyler Bogaczyk, Albert DeNittis et al.
Journal of Clinical Oncology
Colorectal Cancer Surgical Treatments
article

Organ preservation and local excision for rectal cancer: Long-term oncologic outcomes.

Erik L. Zeger, Avihai Moscovici, Tyler Bogaczyk, Albert DeNittis, Hien Anh Ton, John Marks
article en

Abstract

3655 Background: Organ preservation is a desired outcome for rectal cancer patients after neoadjuvant chemoradiotherapy. In patients where a complete response is in question, endoscopically assisted full-thickness local excision offers a great option. Long-term data with this approach is limited. We report our experience with transanal endoscopic microsurgery (TEM) status post chemotherapy. Methods: Between January 2005 and October 2019, from a prospectively maintained rectal cancer database, we identified all patients who underwent TEM for adenocarcinoma after neoadjuvant CRT. Demographic data as well as follow-up interval and oncologic outcomes were reviewed and analyzed. Results: Ninety-two patients who underwent TEM for rectal cancer were included. The mean age was 67 years (32–94), 66% were male, and the mean BMI was 29.3 kg/m² (19.1–43). ASA classifications were II in 38%, III in 51%, and IV in 5% of patients. The mean tumor size was 3.1 cm (1–6) and mean estimated blood loss (EBL) was 29 mL (0–500). Postoperative 30-day morbidity occurred in 6.5% of patients, with no mortalities. The mean follow-up was 57.5 months (0.4-194.5), during which 7.6% of patients developed local recurrence and 6.5% developed systemic metastases. Based on final pathology, 48 patients with a complete pathologic response (ypT0) had local recurrence and distant metastasis rates of 4% and 2%, respectively. In patients with stage I disease (n=35), local recurrence occurred in 11% and distant metastasis occurred in 9%. Stage II patients (n=7) experienced a 14% rate of local recurrence with no distant metastases. Among stage III patients (n=2), both local and distant failure occurred in 50% of cases. Conclusions: TEM after neoadjuvant CRT was associated with excellent oncologic outcomes in patients achieving complete pathologic response. Selected patients with favorable residual disease experienced acceptable recurrence rates, supporting TEM as a potential organ-preserving strategy in this subgroup. In contrast, higher pathologic stage was associated with substantially increased local and distant failure, highlighting the need for strict selection, pathology-driven decision-making, and close surveillance.

Journal of Clinical OncologyVol. 44(16_suppl)
Main Line Health (US), Lankenau Medical Center (US), Illinois CancerCare (US)
Openalex Percentile: Top 12%
Colorectal Cancer Surgical Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.